153 Therapeutics
Advancing treatments for neurodegeneration.
153 Therapeutics
Advancing treatments for neurodegeneration.
About Us
Our Mission
Our Mission
Our Mission
We are focused on developing novel, best-in-class therapeutics for central nervous system (CNS) disorders such as Parkinson’s Disease, Alzheimer’s Disease and ALS, among others. Our unique approach targets nuclear receptors in the brain to regulate transcriptional activity and restore normal signaling and function. Pre-clinical progress
We are focused on developing novel, best-in-class therapeutics for central nervous system (CNS) disorders such as Parkinson’s Disease, Alzheimer’s Disease and ALS, among others. Our unique approach targets nuclear receptors in the brain to regulate transcriptional activity and restore normal signaling and function. Pre-clinical progress to date demonstrates the potential for this approach to yield better therapies for patients.
Our History
Our Mission
Our Mission
Our founding team is from the University of California at San Francisco (UCSF), one of the top neuroscience research institutions in the US. With a successful basic research program funded in part by the NIH and the Michael J. Fox Foundation, the company was spun out and has exclusive licensing rights from UCSF. The founding team has dec
Our founding team is from the University of California at San Francisco (UCSF), one of the top neuroscience research institutions in the US. With a successful basic research program funded in part by the NIH and the Michael J. Fox Foundation, the company was spun out and has exclusive licensing rights from UCSF. The founding team has decades of experience in discovering, developing and bringing new drugs to market.
Our Team
Our Mission
Our Team
Pamela M. England, PhD
Co-Founder
Peter Noymer, PhD
CEO and Co-Founder
Matthew P. Jacobson, PhD
Co-Founder